CURE Pharmaceutical has signed a deal with Canopy Growth Corp (TSX:WEED, NYSE:CGC), where Canopy will have an exclusive license to CURE’s patented, multi-layer oral thin film technology for use with cannabis extracts and biosynthetic cannabinoids.

Jessica Rousset, COO for CURE Pharmaceutical, says the licence agreement allows CURE to accelerate and expand the impact of its technology by joining forces with Canopy, which has broad market access and resources to bring a product to market.

See coverage below:

CURE Pharmaceutical joins forces with Canopy Growth in exclusive partnership (Proactive Investors)
CURE Pharmaceutical Expands Distribution of  CUREfilm Technology With First Licensing Agreement (Drug Development and Delivery)
Canopy Growth Corp. Scores Huge Pharma Deal (Motley Fool)